|Title||Professor and Department Chair|
Dr. Chen is Professor & Chairman of Department of Neurosurgery/Neuro-oncology of Sun Yat-sen University Cancer Center. Dr. Chen is funder president of Chinese Society of Neuro-Oncology. Dr. Chen’s clinical interests include microsurgery and multimodality treatment for primary and metastatic tumors in central nervous system, particularly gliomas. Chemotherapy and immunotherapy are important adjuvant treatments in his clinical practice.
Dr Chen has received many awards including Francis McNaughton Memorial Prize in 1998(Canadian Neurological Society), WHO Prize for Chinese Young Professional in Mental Health & Neuroscience in 1993, and Wang Chong-cheng Academic Award for Chinese Neurosurgeon in 2006.
More than 200 papers have been published in leading scientific journals including Cancer Research, Clinical Cancer Research, Journal of National Cancer Institute, Neurosurgery, Journal of Neurosurgery, Journal of Neuro-oncology, and Neuro-oncology.
Genetic alterations leading to resistance of human brain tumors to chemotherapy, and has found that ERCC2, one of the important components in nucleotide excision repair (NER) system related to alkylating agent resistance in human tumor cell lines. MGMT associated drug resistance in glioma has also been investigated and applied in his clinical practice.He also, for the first time, has found that vasculogenic mimicry (VM), a new circulation exists in malignant gliomas. And, immunotherapy for glioma, such as CIK cell local therapy and DC-glioma fusion cells (FC), is also his investigating field.For information on Professor Chen's laboratory, click here and select: Brain cancer genetic resistance/drug resistance in glioma/vasculogenic mimicry (VM) in glioma
M.D. (1982): Suzhou Medical College, Suzhou, ChinaPh.D.
(1993): Suzhou Medical College, ChinaPost-doctoral fellow/research associate
(1993-1999): McGill University, Montreal, Canada.
1. Chen ZP,MalapetsaA,MarcantonioD,MohrG,BrienS,PanasciLC.Correlation of chloroethylnitrosourearesistancewith ERCC-2 expression in humantumorcelllines as determined by quantitative competitivepolymerasechainreaction. Cancer Research ,1996,56: 2475-2478.
2. Chen ZP,MalapetsaA,BrienS,MohrG,PanasciLC.Quantitation of ERCC-2 expression by reverse-transcription polymerasechainreactioncomparison to Northern blot analysis. Anal Biochem,1997,244: 50-54.
3. Chen ZP,MalapetsaA,McQuillanA,MarcantoniaD,BelloV,MohrG,RemackJ,BrentTP,PanasciLC.Evidence for nucleotide excision repair as a modifying factor of MGMT mediatedinnatechloroethylnitrosourearesistance in humantumorcelllines. Molecular Pharmacology,1997,52: 815-820.
4. Chen ZP,McQuillanA,MohrG,PanasciLC.Excisionrepair cross-complementing rodent repairdificiency gene2 expression and chloroethylnitrosourearesistance in humangliomacelllines. Neurosurgery,1998,42(5)1112-1119.
5. Chen ZP,YaroshD,GarciaY,TampieriD,LanglebenA,MohrG,MalapetsaA,Panasci LC. Relationship Between O6-methylguanine-DNA MethyltransferaseLevels and ClinicalResponseInduced by ChloroethylnitrosoureaTherapy in GliomaPatients.Canadian Journal of Neurological Sciences,1999,26:104-109.
6. Chen ZP,RemackJ,BrentTP,MohrG,PanasciLC.Extraneuronal Monoamine Transporter Expression vis-à-vis SauCNUCytotoxicity in HumanTumorCellLines.Clinical Cancer Research, 1999,5:4186-4190.
7. Chen ZP,WangG,HuangQ,SunZF,ZhouLY,WangAD,PanasciLC.Enhancedantitumoractivity of SarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive humangliomaxenograftmodel.J Neuro-Oncology,1999,44:7-14.
8. Chen ZP,PanJ,HuangQ,SunZF,ZhouLY,WangAD.Antitumorefficacy of SarCNU in a HumanGliomaXenograft Model expressingboth MGMT and Extraneuronal Monoamine Transporter.J Neuro-Oncology,2001,51:19-24.
9. Chen ZP,CarterCA,AlleyMC,MohrG,PanasciLC.Both Extraneuronal Monoamine Transporter and O6-methylguanine-DNA Methyltransferase Expression Influence the AntitumorEfficacy of SarCNU in HumanTumorXenografts.JPharmacolExp Ther,2001,296(3):712-715.
10. Wang ZM,ChenZP,XuZY,ChristodoulopoulosG,BelloV,MohrG,AloyzR,PanasciLC.In vitro evidence for homologousrecombinationalrepair in resistance to melphalan.JNatl Cancer Inst,2001,93(19):1473-1478.
11. Yue WY,ChenZP.Doesvasculogenic mimicry exist in astrocytoma? J Histochem Cytochem.2005, 53(8):997-1002.
12. Chen HY,ShaoCJ,ShiHL,MuYG,SaiK,ChenZP.Singlenucleotidepolymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapydrugcytotoxicity in humangliomas.J Neuro-oncology,2007,82:257-262.
13. ShaoCJ,FuJ,ShiHL,MuYG,ChenZP.Activities of DNA-PK and Ku86, but not Ku70, maypredictsensitivity to cisplatin in humangliomas.J Neurooncol,2008,89(1):27-35.
14. Yue WY,YuSH,ZhaoSG,ChenZP.Molecular markers relating to malignant progression in grade II astrocytoma. J Neurosurgery,2009,110(4):709-14.
15. Fu J,LiuZG,LiuXM,ChenFR,ShiHL,PangJC,NgHK,ChenZP,Glioblastoma stem cells resistant to temozolomide-induceautophagy.chinese medical journal,2009,122(11):1255-1259.
16. Fu J,ShaoCJ,Chen FR,NG HK,ChenZP.Autophagy Induced by Valproic Acid is Associated with Oxidative Stress in Glioma Cell Lines.Neuro-oncology,2010,12(4):328-340.
17. Chen HY,ShaoCJ,ChenFR,KwanAL,ChenZP.Role of ERCC1 Promoter Hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer,2010,126(8):1255-1259.
18. Liu XM,ZhangQP,MuYG,ZhangXH,SaiK,PangJC,NgHK,ChenZP.Clinical significance of vasculogenic mimicry in human gliomas.J Neurooncol,2011,(105 ):73-179.
19. Chen YS,JingZT,LuoC,ZhuangMH,XiaJZ,ChenZP,WangYJ.Vasculogenic mimicry–potential target for glioblastomatherapy:an in vitro and in vivo study.Med Oncol,2012,29:324–331.
20. YueWY,SaiK,WuQL,XiaYF,YuSH,ChenZP.Long-term molecular changes in WHO grade II astrocytomas following radiotherapy.Chin J Cancer,2012,31(3):159-165.
21. Cui L,FuJ,Pang JC, QiuZK,LiuXM,Chen FR, Shi HL,NgHK,ChenZP.Overexpression of IL-7 enhances cisplatin resistance in glioma.Cancer Biology & Therapy ,2012,13 :7,496-503.
22. Shao CJ, Wu MW, Chen FR, Li C, Xia YF, Chen ZP. Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro. Chin Med J, 2012;125(24):4338-4343.
23. Mu YG, Huang LJ, Li SY, Ke C, Chen Y, Jin Y, Chen ZP. Working memory and the identification of facial expression in patients with left frontal glioma. NeuroOncol (2012) 14(suppl 4): iv81-iv89.
24. Wang J,Sai K,Chen FR,Chen ZP. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol. 2013 Jul;72(1):147-158
25. Fu J, Yang QY, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL, Chen ZP.TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. NeuroOncol 2013,15（10）：1353-1365
26. Qiu ZK, Shen D, Chen YS, Yang QY,GuoCC,Feng BH, Chen ZP.Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer, 2013; Vol. 32 Issue.
27. Li G, Zhang ZG, Jin TB,LiangHJ,TuYY,Gong L, Chen zpandGaoGD.High frequency of the X-chromosome inactivationin young female patients with high-grade glioma. Diagnostic Pathology 2013, 8:101.
28. KeSai, Wen-yu Li, Yin-sheng Chen, Jian Wang, Su Guan, Qun-ying Yang, Cheng-chengGuo, Yong-gaoMou, Wei-ping Li, Zhong-ping Chen. Triptolide Synergistically Enhances Temozolomide-induced Apoptosis and Potentiates Inhibition of NF--B Signaling in Glioma Initiating Cells. The American Journal of Chinese Medicine， volume 42, issue 2 (in April 2014)
|Title||Attending professor in the Department of Neurosurgery, doctoral advisor, chief physician and Doctor of Medicine|
He is also a member of the Neurosurgery Branch of Guangdong Medical Association, a member of Neurosurgeons Association of Guangdong Medical Doctor Association, a standing member of the Neurosurgery Branch of Guangdong Association of the Integrative Traditional and Western Medicine, Vice Chairman of Guangdong Anti-cancer Association and Society of Neuro-oncology, Guangzhou Anti-cancer Association, a member of the Branch of Minimally Invasive Therapy for Intracranial Tumors, Committee of Minimally Invasive Therapy, Chinese Anti-cancer Association, and Editorial Board Member of Chinese Journal of Neuro-oncology.Diagnosis and microsurgery treatment of nervous system (brain and spinal cord) tumors; combination therapy (surgery, chemotherapy, targeted therapy and immunotherapy) of brain glioma, and diagnosis and treatment of brain metastasis.
He has also conducted some research on nasopharynx carcinoma radiation encephalopathy, etc. and has carried out intracranial lesions stereotactic biopsy.
Prof. Mou Yonggao is Master and Doctor of Clinical Medicine of Sun Yat-sen University. He has been engaged in clinical work, scientific research and teaching on neurosurgery for over 20 years, and has been committed to clinical work and research work in neuro-oncology. He studied at MD Anderson Cancer Center in 2009.He has led a number of scientific research projects funded by National Natural Science Foundation of China, etc. and published several papers on SCI journals. He was granted a patten for utility model of the People's Republic of China.
Ke Sai, M.D., Ph.D. is an Associate Professor and Secretary in the Department of Neurosurgery, Sun Yat-sen University Cancer Center. Dr. Sai received his medical degree and neurosurgical training in Sun Yat-sen University. He completed a fellowship in neuro-oncology at MD Anderson Cancer Center, USA and was awarded with Trainee Excellence Awards in 2009 at MD Anderson Cancer Center. He is currently the vice president of Chinese Young Neurosurgeon Association and a committee member of Chinese Society of Neuro-oncology. Clinically, Dr. Sai focused on the individualized treatment of tumors in the central nervous system. He is also a translational researcher on novel therapy on gliomas. He has published more than 30 peer-reviewed articles and book chapters.
Glioma drug resistance
Novel therapies against glioma
2009 Ph.D. Sun Yat-sen University, Medical School, P.R.China. Clinical Oncology
2004 M.S. Sun Yat-sen University, Medical School, P.R.China. Clinical Medicine
2002 M.D. Sun Yat-sen University, Medical School, P.R.China. Clinical Medicine
5/2007-4/2009 Postdoctoral fellowship, Department of Neuro-Oncology, UT MD Anderson Cancer Center, TX, U.S.A.
8/2004 The Australia and Asia Pacific Clinical Oncology Research Development Workshop. Sponsord by MOGA, AACR and ASCO
7/2004-12/2006 Clinical Residency, Sun Yat-sen University Cancer Center, Guangzhou, P.R.China
1. Sai K, Zhong MG, Wang J, Chen YS, Mou YG, Ke C, Zhang XH, Yang QY, Lin FH, Guo CC, Chen ZH, Zeng J, Lv YC, Li X, Gao WC, Chen ZP. Safety evaluation of high-doseBCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas. J Neurol Sci. 2014, 343(1-2): 60-65.
2. Wang G, Sai K, Gong F, Yang Q, Chen F, Lin J. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner. Mol Med Rep. 2014, 9(5): 1799-805.
3. Sai K, Li WY, Chen YS, Wang J, Guan S, Yang QY, Guo CC, Mou YG, Li WP, Chen ZP. Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells. Am J Chin Med. 2014, 42(2): 485-503.
4. Fu J, Yang QY, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL, Chen ZP. TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. Neuro Oncol. 2013, 15(10): 1353-1365.
5. Sai K, Mou YG, Zeng J, Lv YC, Xi SY, Guan S, Zhang XH, Wang J, Ke C, Guo JG, Chen YS, Chen ZP. Neurosurgical interventions for patients with nasopharyngeal carcinoma: a single institution experience. World J Surg Oncol. 2013, 11:227.
6. Li ZY, Zhang XH, Chen Y, Guo JG, Sai K, Yang QY, Chen ZP, Mou YG. Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. Onco Targets Ther. 2013, 6: 869-75.
7. Sai K, Yang QY, Shen D, Chen ZP. Chemotherapy for gliomas in mainland China: An overview. Oncol Lett. 2013, 5(5): 1448-1452.
8. Wang J, Sai K, Chen FR, Chen ZP. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol. 2013, 72(1): 147-158.
9. Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.J Neurooncol. 2012, 107(3): 487-501.
10. Yue WY, Sai K(co-first author), Wu QL, Xia YF, Yu SH, Chen ZP. Long-term molecular changes in WHO grade II astrocytomas following radiotherapy. Chin J Cancer. 2012, 31(3): 159-165.
11. Jiang XB, Ke C, Zhang GH, Zhang XH, Sai K, Chen ZP, Mou YG. Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors. BMC Cancer. 2012,12:49.
12. Mou YG, Sai K (co-first author), Wang ZN, Zhang XH, Lu YC, Wei DN, Yang QY, Chen ZP. Surgical management of radiation-induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: Report of 14 cases. Head Neck. 2011, 33(10): 1493-1500.
13. Jiang XB, Yang QY, Sai K, Zhang XH, Chen ZP, Mou YG. Brain metastases from colorectal carcinoma: a description of 60 cases in a single Chinese cancer center. Tumour Biol. 32(6): 1249-1256.
14. Liu XM, Zhang QP, Mu YG, Zhang XH, Sai K, Pang JC, Ng HK, Chen ZP. Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol. 2011, 105(2): 173-9.
15. Sai K, Chen ZP. Schwannoma of the facial nerve involving the middle cranial fossa: case report. Chin Med J (Engl), 2007, 120(24): 2334-2336.
16. Chen H, Shao C, Shi H, Mu Y, Sai K, Chen Z. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma. J Neurooncol, 2007, 82(3): 257-262.Book ChapterKe Sai and Zhong-ping Chen (2011). Chapter 13. Targeting Glioma Stem Cells: Path Leading to the Cure. Cancer Stem Cells - The Cutting Edge, Stanley Shostak (Ed.), ISBN: 978-953-307-580-8, InTech.
|Title||Associate chief physician|
Prof. Wang Jian graduated from Guangzhou Medical University in 1993 and after that worked in the Department of Neurosurgery at the Second Affiliated Hospital of Guangzhou Medical University. He has accumulated rich clinical experience in the diagnosis and treatment of diseases such as nervous system tumors, brain trauma and cerebrovascular disease. He was a student of Liu Yunsheng, a famous Chinese expert in neurosurgery and Professor of Xiangya School of Medicine, Central South University, and was awarded a master's degree and a doctoral degree in neurosurgery in 1997 and 2003 respectively. He had been engaged in postdoctoral research in the Department of Neurosurgery at the University of Florida and conducted sphenoid sinus and temporal bone microdissection studies at Rhoton microdissection laboratory from August 2007 to September 2009.
Currently he serves as the Associate Chief Physician of the Department of Neurosurgery at Sun Yat-sen University Cancer Center and is engaged in clinical work and scientific research. He has carried out in-depth studies on the diagnosis and microsurgery treatment of skull base tumor and pediatric neural tumor. He is also a youth member of the Chinese Society of Neuro-oncology, Chinese Anti-cancer Association, a member of the Society of Pediatric Oncology, Guangdong Anti-cancer Association, and Editorial Board Member of the Chinese Journal of Neuro-oncology.
He has published over 20 papers on professional journals in and outside China and participated in the compilation and translation of three books on neurosurgery, namely Practical Microsurgery of Skull Base, Endoscopic Skull Base and Brain Surgery: Tips and Pearls, and Rhoton Cranial Microanatomy and Surgical Approaches. He was awarded the First Class of Scientific and Technological Progress Award at provincial level.
|Title||Associate chief physician and specialist in neuro-oncology chemotherapy|
Prof. Yang is a specialist in neurosurgery and neuro-oncology chemotherapy as well as a member in the glioma single disease expert group at Sun Yat-sen University Cancer Center. In 2012, she studied clinical neuro-oncology at the University of Texas MD Anderson Cancer Center which ranks first in tumor combination therapy in America. In 2013, she served as a visiting scholar at the Neurosurgery and Brain Tumor Center of Prince of Wales Hospital, the Chinese University of Hong Kong and was engaged in the clinical work on neuro-oncology. She has been engaged in clinical chemotherapy and combination therapy of various malignant tumors for over ten years. Through diagnosis and treatment on quite a number of brain metastasis and primary brain tumor patients, she has carried out a series of studies and exploration on nervous system tumors. She is one of the first batch of specialists in neuro-oncology chemotherapy in China. She has rich experience in chemotherapy of primary central nervous system tumor, brain metastasis and children and teenager malignant tumors. She is skilled in chemotherapy and individualized combination therapy for brain glioma, brain germ cell tumor, medulloblastoma, primitive neuroectodermal tumor, neuroblastoma, primary central nervous system lymphoma, malignant meningioma, ependymoma and brain metastasis, etc. She has been in charge of holding six "National Neuro-oncology Chemotherapy and Molecularly Targeted Drug Therapy Study Group" (national level continuing medical education program) since 2007.
She has participated in a number of multi-centric clinical trials of anti-tumor new drug (cytotoxic drug and molecularly targeted therapy drug) in and outside China. She has received a number of scientific research funds from National Natural Science Foundation of China, project of Development Center for Medical Science and Technology, Ministry of Health, P.R.China, project of Guangdong Provincial Department of Science and Technology, scientific research project of Health Department of Guangdong Province, project funded by Guangdong Provincial Association for Science and Technology (fund for young and middle-aged scientists and technicians to go abroad to participate in international academic conferences), and fund for scientific research on single diseases of Sun Yat-sen University Cancer Center. She is the Chief Editor of Handbook of Nervous System Tumor Chemotherapy. She also participated in the compilation of books such as Nervous System Tumors, and Clinical Practice Guidelines for Central Nervous System Tumors. And she has published over 30 papers in SCI journals and Chinese core journals.
Chemotherapy, molecularly targeted therapy and combination therapy for nervous system tumors.
1. Fu J, Yang QY（共同第一作者）, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL, Chen ZP. TGM2 inhibition attenuates ID1 expression in CD44-high glioma -initiating cells.Neuro Oncol, 2013,15（10）：1353-1365. （SCI-IF:6.18分)
2. KE SAI,QUN-YING YANG,DONG SHEN,ZHONG-PING CHEN.Chemotherapy for gliomas in mainland China:An overview.ONCOLOGY LETTERS,2013,5:1448-1452.
3. Jiang XB,Yang QY,Sai K,Zhang XH,Chen ZP,Mou YG.Brain metastases from colorectal carcinoma: a description of 60 cases in a single Chinese cancer center.Tumour Biol,2011,32(6):1249-1256.
4. Chen LK,Liang Y,Yang QY, Xu F,Zhou NN,Xu GC,Liu GZ,Wei WD.Triplet platinum -based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev,2012;13(5):1863-1867.
5. Zhang GH,Jiang XB,Zhang XH,Sai K,Yang QY,Chen ZP,Mou YG.Correlation between TGF-β1 expression and Treg cell infiltration in glioma.Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi,2011,27(6):680-682.
6. Mou YG, Sai K, Wang ZN, Zhang XH, Lu YC, Wei DN, Yang QY, Chen ZP. Surgical management of radiation-induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: Report of 14 cases.Head Neck,2011,33(10):1493-500.
7. Zhen-ye Li, Xiang-heng zhang，Yu Chen，Jian-gui Guo，Ke Sai，Qun-ying Yang， Zhong-ping Chen，Yong-gao Mou, .Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. OncoTargets and Therapy, 2013:6 869–875.( SCI-IF:2.073)